skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Yesterday on BNN you said that GUD was probably #3 in Canadian medical - who is #1 & #2.

Thank you as always.
Read Answer Asked by Craig on June 02, 2015
Q: Hello Team
As you know the FDA has granted Fast Track designation to Intellipharmaceuticals abuse deterrent Oxycodone ( Rexistra ). In a nutshell what are the next steps the company would take to get their product to market such as licensing, selling rights, getting production set up etc? How does it all work? Does Intellipharmaceuticals have the financial might to accomplish the task or will they need help? What is a typical time frame between approval and marketing for a product such as this. Considering the issues around the abuse of Oxycondin I expect that Intellipharmaceutis have a good product and opportunity.
Have a Good weekend
Thanks for your help
Clarence
Read Answer Asked by Clarence on June 01, 2015
Q: I have recently moved back into the health care sector with half positions in CRH, CXR and NHC. I'm looking to add to my holdings. How would you rank these three names as well as PHM (or any others).
Thanks for your great service.
Dennis
Read Answer Asked by Dennis on June 01, 2015
Q: Hi,

Thanks for suggestion that VRX would be a good candidate for a covered call. I bought 100 shares around $270 in early May and wrote a July $300 call for about $1,500. (Un)fortunately, the stock rose quite a lot so now option is in money. Any suggestions what to do? (i.e., do you like VRX enough to suggest I should buy option at a loss so my position isn't exercised?). Thanks for great service!
Read Answer Asked by Steven on May 29, 2015
Q: Hi Peter & team, Is there anything you know is causing GUD to keep falling.
Thank you!
Read Answer Asked by Silvia on May 28, 2015
Q: Hello,

Wondering if you can comment on content below from Neptune's earnings release today? Do you see upside from here? It was apparently up 3.6% after hours in US market though at first glance it's hard to see the positive. I have a small position having bought just over $2 and wonder if it is a buy, sell or hold and why?

Neptune Technologies reports Q4 net loss of $10.68 mln vs loss of $1.33 mln in prior year, revs $4.02 mln vs $3.67 mln in prior year (1.40 +0.04)
Q4 adjusted gross margin was 26% vs 20% in prior year. "In line with Neptune's decision to slow production down to address product handling characteristics, consolidated sales for the first quarter ending May 31, 2015 are expected to come in at approximately $2.0 million, while the gross margin will remain under pressure. However, with the positive momentum we are seeing at the plant and a robust sales pipeline we expect sales for the second quarter ending August 31, 2015 to be materially higher."

Read Answer Asked by Tim on May 28, 2015
Q: Hi Peter/group
I own the following health care stocks
- CXR
- MSL
- PHM
- XLV
- GUD
Recently I sold Catamaran (CCT)and on your recommendation I purchased CXR unfortunately it has gone down 15% in a month my question is take the loss and sell or?...Thanks for your thoughts... PS CXR seems to be getting especially hit hard as it is up substantially this year
Read Answer Asked by Terence on May 27, 2015
Q: Hi . Wondering if you could tell me which of the health insurance cos could merge. I have Aetna.
Any insight on health care companies which might do the same, or pharma companies?
Many thanks for your service.
Read Answer Asked by Helen on May 25, 2015
Q: Considering all the death crosses in their chart, it looks like Biosyent is in a condition where the technical indicators will rule the fundamentals for a bit. I bought it at the top end in an RRSP and TFSA (3%)so is it worth holding. Was the stock just stretched out too far in Q1 or are there some fundamental concerns? I don't have any issue holding on for a couple of quarters or buying a bit more when it bottoms if there are no serious fundamental concerns.
Read Answer Asked by Clarence on May 24, 2015
Q: When you calculate insider ownership, do you count shares such as options, indirect ownership and restricted rights shares equally with directly held shares. Now that CXV have started their acquisition process what is their insider holdings percentage? Is there any indication of what the contributions of these two acquisitions will be towards CXV's bottom line?
Read Answer Asked by Clarence on May 22, 2015
Q: Hello,

Since Jason Donville recommended Biosyent (RX) on December 24 I was in on what I perceived was a dip and luckily out again before it dipped another big chunk. Similar thing with Knight (GUD).

My question is whether there is a price point at which either of these become "no brainer" buys? For an investor willing to absorb some risk are we near that point with each stock at $7?
Read Answer Asked by Tim on May 21, 2015
Q: Thanks for taking my question. You last commented on this company in early 2014. Could you provided an updated point of view on its level of attractiveness?
Read Answer Asked by Neil on May 19, 2015
Q: I recently took profits and sold 3/4 of my position in Nobilis Health (NHC), as I did not feel comfortable with earnings "attributable to noncontrolling interests" being higher than those attributable too NHC (which resulted in a net loss for the quarter). Is this a concern? And how is this calculated?

I am thinking about re-investing the NHC cash into RX and/or GUD. Is there any reason why the market seems to be reacting negatively to RX's recent quarterly results (which actually beat consensus) or is this sell off just sector or valuation related? Also, I note that RX trades at a massive P/B ratio. Is this a concern? Is this a good entry point for RX?

And would you prefer GUD to RX or just buy both? I am fairly risk tolerant and my only other position in the health/biotech sector currently is PHM.

Thanks! Feel free to dock me a couple question credits for this doozy...
Read Answer Asked by Scott on May 19, 2015
Q: do you have any new opinions on Convalo health.By my calculations the company has about .39 cents in cash.Stock trading at .55 .Thank you
Read Answer Asked by glenn on May 19, 2015
Q: After being a top pick of Jason Donville on Dec 24/14,RX's price increased to $12.08 on Dec 31,but it had steadily & sharply declined to $7.57 on May 14 despite 2 good quarterly reports @ end of Feb & May 13.I am really confused.I bought a small amount @ $10. Please advise if this is a Hold,Sell or average down,Thanks for your normal great opinions & services
Read Answer Asked by Peter on May 19, 2015
Q: May I have your opinion on the current results?
Thanks
Read Answer Asked by Denis on May 15, 2015
Q: Looks like they made some anti cancer drug breakthrough on tissue samples? Hate to miss a big rise if it happens, since I have been looking at this one for awhile. Do you think this development is for real?
Read Answer Asked by David on May 15, 2015
Q: Hello Peter,
Any new news on gud, stock is really pulling back and I am wondering if Mr Goodman is leaving.
Read Answer Asked by ron on May 15, 2015